Tomorrow's Cell
Therapies, Today®
Pluristyx provides induced pluripotent stem cells and the expertise to accelerate the development and commercialization of revolutionary cellular therapies.
We Simplify the Stem Cell Therapy
Development Process
We Simplify the Stem Cell Therapy
Development Process
Why Pluristyx?
Pluristyx's innovative technologies, provides clients with the necessary expertise and tools to support and accelerate the development and commercialization of cellular products.
Our iPSC platform offers our clients a single point of access to our research and clinical grade stem cells, proprietary gene edits and end-to-end support throughout the product development pathway.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
Try Before You Buy
Would you like to experience our technology firsthand before committing to a license agreement? We welcome you to have access to our various product offerings before you purchase a commercial license.
Your Problems, Our Solution
To overcome any obstacle you’re facing, Pluristyx offers a novel iPSC platform for rapid, efficacious, and high-quality iPS cell therapy development, can turn your bold ideas into reality.
Your Problems,
Our Solution
To overcome any obstacle you’re facing, Pluristyx offers a novel platform for rapid, efficacious, and high-quality iPSC therapy development, can turn your bold ideas into reality.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
Latest News
Mytos and Pluristyx Enter Strategic Collaboration to Manufacture GMP Line for Regenerative Medicines
London / Seattle – Mytos, a leader in automated regenerative medicine manufacturing and Pluristyx, a leading provider of GMP induced pluripotent stem cell (iPSC) based solutions, today announced a strategic collaboration to automate the manufacture of Pluristyx’s clinical-grade cell lines...
Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
Pluristyx to lead a new public-private consortium with 9 other industry leaders to establish global standards for non-animal drug testing models SEATTLE, WA – December 2, 2025 – Pluristyx, Inc. today announced the formation of the Organoid COMMONS (Consortium for...
Pluristyx Collaborates with Breakthrough T1D to Make "Immune-Cloaked" and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies
Seattle, WA – November 17, 2025 – Pluristyx announced today the launch of a project up to $1.4 million, supported and funded by Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The project...